Press Releases

CRANBURY, N.J., May 13, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its third quarter ended March 31, 2015.  Recent Highlights Launched reconnectstudy.com in support of our Bremelanotide Phase 3 […]

CRANBURY, N.J., May 8, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its third quarter, fiscal year 2015 operating results on Wednesday, May 13, 2015 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May

CRANBURY, N.J., March 6, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that it will be presenting at the 27th Annual ROTH Conference on Wednesday, March 11, 2015, at 10:30 a.m. Pacific Time.  The conference will be held at the Ritz Carlton Laguna Niguel in Dana Point, CA. Carl Spana, Ph.D., President and

CRANBURY, N.J., Feb. 20, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has launched a clinical trial website (https://www.reconnectstudy.com) in support of its phase 3 reconnect study with bremelanotide for

CRANBURY, N.J., Feb. 13, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2014.  “We achieved a significant clinical and corporate milestone by advancing bremelanotide

CRANBURY, N.J., Feb. 9, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its second quarter, fiscal year 2015 operating results on Friday, February 13, 2015 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 13,

CRANBURY, N.J., Feb. 6, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 17th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 17th Annual BIO CEO & Investor Conference will take place February 9-10 at the Waldorf Astoria in New York City.

Triggers euro 2.5 Million (~$3 Million) Milestone Payment from Gedeon Richter CRANBURY, N.J., Dec. 29, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has started its bremelanotide pivotal registration program. 

CRANBURY, N.J. and FARMINGTON, Conn., Dec. 24, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that it has closed on a private placement of 2,050,000 shares of its common stock and

CRANBURY, N.J., Nov. 18, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2014.  Recent Highlights Bremelanotide development for Female Sexual Dysfunction (FSD): €7.5M ($9.8M)